메뉴 건너뛰기




Volumn 41, Issue 2, 2013, Pages 134-142.e3

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; LENALIDOMIDE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

EID: 84873486267     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.10.004     Document Type: Article
Times cited : (79)

References (21)
  • 1
    • 70350433797 scopus 로고    scopus 로고
    • The role of complete response in multiple myeloma
    • Harousseau J.L., Attal M., Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009, 114:3139-3146.
    • (2009) Blood , vol.114 , pp. 3139-3146
    • Harousseau, J.L.1    Attal, M.2    Avet-Loiseau, H.3
  • 2
    • 67349225687 scopus 로고    scopus 로고
    • Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete remission and molecular remission in allografted patients with multiple myeloma
    • Kröger N., Badbaran A., Lioznov M., et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete remission and molecular remission in allografted patients with multiple myeloma. ExpHematol 2009, 37:791-798.
    • (2009) ExpHematol , vol.37 , pp. 791-798
    • Kröger, N.1    Badbaran, A.2    Lioznov, M.3
  • 3
    • 33947197286 scopus 로고    scopus 로고
    • A comparison of allografting with autografting for newly diagnosed myeloma
    • Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110-1120.
    • (2007) N Engl J Med , vol.356 , pp. 1110-1120
    • Bruno, B.1    Rotta, M.2    Patriarca, F.3
  • 4
    • 0032895599 scopus 로고    scopus 로고
    • Molecular and clinical remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma
    • Corradini P., Voena C., Tarella C., et al. Molecular and clinical remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 1999, 17:208-215.
    • (1999) J Clin Oncol , vol.17 , pp. 208-215
    • Corradini, P.1    Voena, C.2    Tarella, C.3
  • 5
    • 0041438792 scopus 로고    scopus 로고
    • Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
    • Corradini P., Cavo M., Lokhorst H., et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003, 102:1927-1929.
    • (2003) Blood , vol.102 , pp. 1927-1929
    • Corradini, P.1    Cavo, M.2    Lokhorst, H.3
  • 6
    • 36349010285 scopus 로고    scopus 로고
    • Multiple Myeloma (009) study Investigators. Lenalidomide plus dexamethsone for relapsed multiple myeloma in North America
    • Weber D.M., Chen C., Niesvizky R., et al. Multiple Myeloma (009) study Investigators. Lenalidomide plus dexamethsone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
    • (2007) N Engl J Med , vol.357 , pp. 2133-2142
    • Weber, D.M.1    Chen, C.2    Niesvizky, R.3
  • 7
    • 36349023319 scopus 로고    scopus 로고
    • Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    • Dimopoulos M., Spencer A., Attal M., et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
    • (2007) N Engl J Med , vol.357 , pp. 2123-2132
    • Dimopoulos, M.1    Spencer, A.2    Attal, M.3
  • 8
    • 76749162262 scopus 로고    scopus 로고
    • Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells
    • Lioznov M., El-Cheikh J., Hoffmann F., et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010, 45:349-353.
    • (2010) Bone Marrow Transplant , vol.45 , pp. 349-353
    • Lioznov, M.1    El-Cheikh, J.2    Hoffmann, F.3
  • 9
    • 18244428600 scopus 로고    scopus 로고
    • Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant
    • Bladé J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
    • (1998) Br J Haematol , vol.102 , pp. 1115-1123
    • Bladé, J.1    Samson, D.2    Reece, D.3
  • 10
    • 78649707335 scopus 로고    scopus 로고
    • Lenalidomide mode of action: linking bench and clinical findings
    • Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 24 Suppl 1:13-19.
    • Blood Rev , vol.24 , Issue.SUPPL 1 , pp. 13-19
    • Davies, F.1    Baz, R.2
  • 11
    • 77955092382 scopus 로고    scopus 로고
    • Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer Cells
    • Dauguet N., Fournié J.J., Poupot R., Poupot M. Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer Cells. Cell Immunol 2010, 264:163-170.
    • (2010) Cell Immunol , vol.264 , pp. 163-170
    • Dauguet, N.1    Fournié, J.J.2    Poupot, R.3    Poupot, M.4
  • 12
    • 28844472902 scopus 로고    scopus 로고
    • Lenalidomide and thalidomide: mechanisms of action-similarities and differences
    • Anderson K.C. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 2005, 42:S3-S8.
    • (2005) Semin Hematol , vol.42
    • Anderson, K.C.1
  • 13
    • 20444463165 scopus 로고    scopus 로고
    • Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma
    • Kröger N., Shaw B., Iacobelli S., et al. Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005, 129:631-643.
    • (2005) Br J Haematol , vol.129 , pp. 631-643
    • Kröger, N.1    Shaw, B.2    Iacobelli, S.3
  • 14
    • 60249098439 scopus 로고    scopus 로고
    • Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenousleukemia
    • Cooley S., Trachtenberg E., Bergemann T.L., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenousleukemia. Blood 2009, 113:726-732.
    • (2009) Blood , vol.113 , pp. 726-732
    • Cooley, S.1    Trachtenberg, E.2    Bergemann, T.L.3
  • 15
    • 0037086131 scopus 로고    scopus 로고
    • Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
    • Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
    • (2002) Science , vol.295 , pp. 2097-2100
    • Ruggeri, L.1    Capanni, M.2    Urbani, E.3
  • 16
    • 80054016181 scopus 로고    scopus 로고
    • Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
    • Kröger N., Zabelina T., Berger J., et al. Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 2011, 25:1657-1661.
    • (2011) Leukemia , vol.25 , pp. 1657-1661
    • Kröger, N.1    Zabelina, T.2    Berger, J.3
  • 17
    • 80052398586 scopus 로고    scopus 로고
    • Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial
    • Kneppers E., van der Holt B., Kersten M.J., et al. Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood 2011, 118:2413-2419.
    • (2011) Blood , vol.118 , pp. 2413-2419
    • Kneppers, E.1    van der Holt, B.2    Kersten, M.J.3
  • 18
    • 79551615800 scopus 로고    scopus 로고
    • The immunostimulatory effect of lenalidomide on NK cell function is profoundly inhibited by concurrent dexamethasone therapy
    • Hsu A.K., Quach H., Tai T., et al. The immunostimulatory effect of lenalidomide on NK cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011, 117:1605-1613.
    • (2011) Blood , vol.117 , pp. 1605-1613
    • Hsu, A.K.1    Quach, H.2    Tai, T.3
  • 19
    • 77950644007 scopus 로고    scopus 로고
    • Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function
    • Gandhi A.K., Kang J., Capone L., et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010, 10:155-167.
    • (2010) Curr Cancer Drug Targets , vol.10 , pp. 155-167
    • Gandhi, A.K.1    Kang, J.2    Capone, L.3
  • 20
    • 80855156719 scopus 로고    scopus 로고
    • Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
    • Zhu Y.X., Braggio E., Shi C.X., et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011, 118:4771-4779.
    • (2011) Blood , vol.118 , pp. 4771-4779
    • Zhu, Y.X.1    Braggio, E.2    Shi, C.X.3
  • 21
    • 70449719357 scopus 로고    scopus 로고
    • Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis
    • Chiron D., Pellat-Deceunynck C., Maillasson M., et al. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. J Immunol 2009, 183:4371-4377.
    • (2009) J Immunol , vol.183 , pp. 4371-4377
    • Chiron, D.1    Pellat-Deceunynck, C.2    Maillasson, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.